Clinical Trial

Effect of Ezetimibe on Gut Microbiota

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Ezetimibe exerts its primary effects by inhibiting intestinal cholesterol absorption through the NPC1L1 protein. Beyond this, its impact on gut microbiota remains an area of interest. Gut microbiota has been implicated in cholesterol metabolism and CVD pathogenesis through metabolic and non-metabolic pathways. Modulating gut microbiota has been explored as a potential strategy to prevent CVDs. Despite its intestinal mechanism, the influence of ezetimibe on gut microbiota composition has not been thoroughly investigated. Future studies are needed to elucidate its potential interactions with gut microbial communities and their implications for cholesterol metabolism and cardiovascular health.
Trial Details
NCT Number NCT06784557
Lead Sponsor Yonsei University
Conditions Atherosclerotic Cardiovascular Disease With Dyslipidemia
Enrollment 110 participants
Start Date 2024-02-28
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-20